Cross‐company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group
Quality functions from pharmaceutical sponsor companies aim to increase the use of analytics in their oversight of Good Clinical Practices and Pharmacovigilance activities. To leverage and accelerate progress, several companies decided to establish a collaborative model. The goals of this collaborat...
Main Authors: | Timothé Ménard, Kyle Young, Laura Siegel, Jennifer Emerson, Robert Studt, Leslie Sidor, The IMPALA Industry Group |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-08-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.12677 |
Similar Items
-
Leveraging analytics to assure quality during the Covid-19 pandemic - The COVACTA clinical study example
by: Timothé Ménard, et al.
Published: (2020-12-01) -
Protozoa and digestive tract parameters of the impala
by: Dirk Booyse, et al.
Published: (2011-10-01) -
Meat quality parameters of the impala (Aepyceros melampus)
by: Kritzinger, Brian
Published: (2012) -
Seismic damage mechanism at Impala Platinum mine
by: Ledwaba, Lesiba Shalkie
Published: (2013) -
Biochemical Polymorphism in the South African Impala (<i>Aepyceros Melampus</i>)
by: D. R Osterhoff, et al.
Published: (1972-12-01)